Date: August 24, 2021
Time: 8:00am (PST), 11:00am (EST)
Liver cancer is the third cause of cancer-related mortality worldwide. Most patients have chronic liver disease, which has allowed implementing programs for early detection to increase survival. In recent years, nine new systemic agents have been approved by the FDA for patients with advanced stage tumors, but there is uncertainty on the best approach to sequence therapies to maximize efficacy while minimizing drug toxicity. We have developed methods using liquid biopsy to increase early detection rates of liver cancer and prediction of response to systemic therapies.
In this webinar, you will hear Dr. Villanueva:
Explain the singularities and unmet clinical needs in patients with primary liver cancer
Describe the role of liquid biopsy in biomarker development
Share experience using SureSelect XTHS kit for mutation calling in circulating tumor DNA
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.